The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51
Open accessAbstract
BACKGROUND: Pfs25 and Pvs25, surface proteins of mosquito stage of the malaria parasites P. falciparum and P. vivax, respectively, are leading candidates for vaccines preventing malaria transmission by mosquitoes. This single blinded, dose escalating, controlled Phase 1 study assessed the safety and immunogenicity of recombinant Pfs25 and Pvs25 formulated with Montanide ISA 51, a water-in-oil emulsion. METHODOLOGY/PRINCIPAL FINDINGS: The trial was conducted at The Johns Hopkins Center for Immunization Research, Washington DC, USA, between May 16, 2005-April 30, 2007. The trial was designed to enroll 72 healthy male and non-pregnant female volunteers into 1 group to receive adjuvant control and 6 groups to receive escalating doses of the vaccines. Due to unexpected reactogenicity, the vaccination was halted and only 36 volunteers were enrolled into 4 groups: 3 groups of 10 volunteers each were immunized with 5 microg of Pfs25/ISA 51, 5 microg of Pvs25/ISA 51, or 20 microg of Pvs25/ISA 51, respectively. A fourth group of 6 volunteers received adjuvant control (PBS/ISA 51). Frequent local reactogenicity was observed. Systemic adverse events included two cases of erythema nodosum considered to be probably related to the combination of the antigen and the adjuvant. Significant antibody responses were detected in volunteers who completed the lowest scheduled doses of Pfs25/ISA 51. Serum anti-Pfs25 levels correlated with transmission blocking activity. CONCLUSION/SIGNIFICANCE: It is feasible to induce transmission blocking immunity in humans using the Pfs25/ISA 51 vaccine, but these vaccines are unexpectedly reactogenic for further development. This is the first report that the formulation is associated with systemic adverse events including erythema nodosum. TRIAL REGISTRATION: ClinicalTrials.gov NCT00295581.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Weltgesundheitsorganisation (2005) · Cited by 3,799
Insecticide-treated bed nets and curtains for preventing malaria
Lengeler, C. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000363.pub2 · Cited by 1,700
Stoute, J. A., Slaoui, M., Heppner, D. G., Momin, P., Kester, K. E., Desmons, P., Wellde, B. T., Garçon, N., Krzych, U., Marchand, M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701093360202 · Cited by 870
Elements of Large-Sample Theory
Strawderman, W. E., Lehmann, E. L., & Holmes, S. P. (2012) · Selected Works of E. L. Lehmann · doi:10.1007/978-1-4614-1412-4_97 · Cited by 818
Elements of Large-Sample Theory
(1999) · Springer Texts in Statistics · doi:10.1007/b98855 · Cited by 677
Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines
Aucouturier, J., Dupuis, L., Deville, S., Ascarateil, S., & Ganne, V (2002) · Expert Review of Vaccines · doi:10.1586/14760584.1.1.111 · Cited by 308
Muderspach, L. I., Wilczynski, S. P., Roman, L. D., Bade, L., Felix, J. C., Small, L., Kast, W. M., Fascio, G., Marty, V., & Weber, J. S. (2000) · PubMed · Cited by 304
Malkin, E. M., Diemert, D. J., McArthur, J. H., Perreault, J. R., Miles, A. P., Giersing, B. K., Mullen, G. E., Orcutt, A., Muratova, O., Awkal, M., et al. (2005) · Infection and Immunity · doi:10.1128/iai.73.6.3677-3685.2005 · Cited by 246
Self-citationPhase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria
Malkin, E. M., Durbin, A. P., Diemert, D. J., Sattabongkot, J., Wu, Y., Miura, K., Long, C. A., Lambert, L., Miles, A. P., Wang, J., et al. (2005) · Vaccine · doi:10.1016/j.vaccine.2004.12.019 · Cited by 239
Self-citationMiura, K., Orcutt, A. C., Muratova, O. V., Miller, L. H., Saul, A., & Long, C. A. (2008) · Vaccine · doi:10.1016/j.vaccine.2007.10.064 · Cited by 228
Self-citationQuakyi, I. A., Carter, R., Rener, J., Kumar, N., Good, M. F., & Miller, L. H. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.12.4213 · Cited by 195
Self-citationAudran, R., Cachat, M., Lurati, F., Soé, S., Leroy, O. Y., Corradin, G., Druilhe, P., & Spertini, F. (2005) · Infection and Immunity · doi:10.1128/iai.73.12.8017-8026.2005 · Cited by 153
Saul, A. J., Lawrence, G., Smillie, A., Rzepczyk, C. M., Reed, C., Taylor, D. F., Anderson, K., Stowers, A. W., Kemp, R. J., Allworth, A. M., et al. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00175-9 · Cited by 140
Self-citationThe use of oil adjuvants in therapeutic vaccines
Aucouturier, J., Ascarateil, S., & Dupuis, L. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.01.116 · Cited by 120
Transmission-Blocking Vaccines
Kaslow, D. C. (2002) · KARGER eBooks · doi:10.1159/000058850 · Cited by 101
Miles, A. P., McClellan, H., Rausch, K. M., Zhu, D., Whitmore, M. D., Singh, S. P., Martin, L. B., Wu, Y., Giersing, B. K., Stowers, A. W., et al. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.08.049 · Cited by 99
Self-citationMiura, K., Keister, D. B., Muratova, O. V., Sattabongkot, J., Long, C. A., & Saul, A. J. (2007) · Malaria Journal · doi:10.1186/1475-2875-6-107 · Cited by 97
Self-citationImmunotherapy of Advanced Breast Cancer With a Heterophilic Ganglioside (NeuGcGM3) Cancer Vaccine
Carr, A., Rodríguez, E., Arango, M. D. C., Camacho, R., Osorio, M., Gabri, M. R., Carrillo, G., del Pozo, Z. V., Bebelagua, Y., Pérez, R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.124 · Cited by 97
Tsai, C. W., Duggan, P. F., Shimp, R. L., Miller, L. H., & Narum, D. L. (2005) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2005.08.025 · Cited by 81
Self-citationZou, L., Miles, A. P., Wang, J., & Stowers, A. W. (2003) · Vaccine · doi:10.1016/s0264-410x(02)00701-6 · Cited by 75
Self-citationRevisiting Freund's incomplete adjuvant for vaccines in the developing world
Miller, L. H., Saul, A. J., & Mahanty, S. (2005) · Trends in Parasitology · doi:10.1016/j.pt.2005.07.005 · Cited by 46
Self-citationMiles, A. P., Zhang, Y., Saul, A. J., & Stowers, A. W. (2002) · Protein Expression and Purification · doi:10.1006/prep.2001.1613 · Cited by 41
Self-citationHuman Immunity and the Design of Multi-Component, Single Target Vaccines
Saul, A. J., & Fay, M. P. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000850 · Cited by 40
Self-citationEfficacy model for mosquito stage transmission blocking vaccines for malaria
Saul, A. J. (2008) · Parasitology · doi:10.1017/s0031182008000280 · Cited by 34
Self-citation
Cited by
From carbohydrate leads to glycomimetic drugs
Ernst, B., & Magnani, J. L. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2852 · Cited by 820
Bousema, T., & Drakeley, C. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00051-10 · Cited by 746
Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite
Mueller, I., Galinski, M. R., Baird, J. K., Carlton, J. M., Kochar, D. K., Alonso, P. L., & del Portillo, H. A. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70177-x · Cited by 661
New horizons in adjuvants for vaccine development
Reed, S. G., Bertholet, S., Coler, R. N., & Friede, M. (2009) · Trends in Immunology · doi:10.1016/j.it.2008.09.006 · Cited by 618
New horizons in adjuvants for vaccine development
Reed, S. G., Tomai, M., & Gale, M. J. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.08.008 · Cited by 554
Metadata
- Authors
- Wu, Y., Ellis, R. D., Shaffer, D., Fontes, E., Malkin, E. M., Mahanty, S., Fay, M. P., Narum, D., Rausch, K., Miles, A. P., Aebig, J., Orcutt, A., Muratova, O., Song, G., Lambert, L., Zhu, D., Miura, K., Long, C., Saul, A., Miller, L. H., & Durbin, A. P.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-07-09
- Volume
- 3
- Issue
- 7
- Pages
- e2636
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2074905094
- Cited by
- 449
- References
- 25
- FWCI
- 25.73
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.